Phio Pharmaceuticals Corp Overview
Industry: Biotechnology
Sector: Healthcare
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy; PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in T and tumor cells; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Phio Pharmaceuticals Corp is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Phio Pharmaceuticals Corp in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Phio Pharmaceuticals Corp Competitors
Phio Pharmaceuticals Corp operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans